The management of chemotherapy-induced nausea and vomiting (Q39758993)

14 September 2017

1 reference

title

The management of chemotherapy-induced nausea and vomiting (English)

1 reference

14 September 2017

Gralla RJ

1

1 reference

14 September 2017

Tyson LB

series ordinal

2

1 reference

14 September 2017

Kris MG

series ordinal

3

1 reference

14 September 2017

Clark RA

series ordinal

4

1 reference

14 September 2017

1 March 1987

1 reference

Medical Clinics of North America

14 September 2017

1 reference

14 September 2017

71

1 reference

14 September 2017

2

1 reference

14 September 2017

289-301

1 reference

High-dose dexamethasone for prevention of cis-platin-induced vomiting

14 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Dexamethasone and high dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Metoclopramide: dose-related toxicity and preliminary antiemetic studies in children receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Antiemetic effect of oral versus intravenous metoclopramide in patients receiving cisplatin: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Neuropharmacology of Chemotherapy-induced Emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

A comparison of the antiemetic efficacy of prochlorperazine and metoclopramide for the treatment of cisplatin-induced emesis: a prospective, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Oral metoclopramide and cisplatin chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Superiority of Nabilone over Prochlorperazine as an Antiemetic in Patients Receiving Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Extrapyramidal reactions with high-dose metoclopramide

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Lorazepam in cancer patients treated with cisplatin: a drug having antiemetic, amnesic, and anxiolytic effects

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Optimizing metoclopramide control of cisplatin-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Behavioral Treatment for the Anticipatory Nausea and Vomiting Induced by Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

The antiemetic efficacy of secobarbital and chlorpromazine compared to metoclopramide, diphenhydramine, and dexamethasone. A randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

Review of cannabinoids and their antiemetic effectiveness.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

The pharmacology and clinical effectiveness of phenothiazines and related drugs for managing chemotherapy-induced emesis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-7125%2816%2930871-9

7 January 2021

10.1016/S0025-7125(16)30871-9

Identifiers

DOI

0 references

1 reference